Sandra Calvin

SVP, CHIEF ACCOUNTING OFFICER · 1 filing · Latest: Apr 14, 2026

Travere Therapeutics, Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TVTX	Sandra Calvin	SVP, CHIEF ACCOUNTING OFFICER	Apr 14, 2026	Sale	$41.07	21,977	$902.6K	42,353	Apr 16 4:05 PM
TVTX	Sandra Calvin	SVP, CHIEF ACCOUNTING OFFICER	Apr 14, 2026	Option Exercise	$16.05	15,250	$244.8K	64,330	Apr 16 4:05 PM